<DOC>
	<DOCNO>NCT01300247</DOCNO>
	<brief_summary>This open-label , 2-arm , nonrandomized , multicenter , Phase Ib study investigate safety efficacy obinutuzumab ( RO5072759 ; GA101 ) administer combination chemotherapy ( bendamustine fludarabine + cyclophosphamide [ FC ] regimens ) participant previously untreated cluster differentiation 20 ( CD20 ) -positive B-CLL . Participants enrol receive maximum 6 cycle obinutuzumab ( 1000 milligram [ mg ] intravenous [ IV ] infusion , Days 1 , 8 15 Cycle 1 Day 1 Cycles 2 - 6 ) plus bendamustine ( 90 milligram per meter square [ mg/m^2 ] IV , Days 2 3 Cycle 1 Days 1 2 Cycles 2 - 6 ) 28 day cycle maximum 6 cycle obinutuzumab ( 1000 mg IV infusion , Days 1 , 8 15 Cycle 1 Day 1 Cycles 2 - 6 ) plus FC ( fludarabine 25 mg/m^2 IV Days 2 , 3 4 Cycle 1 Days 1 , 2 3 Cycles 2 - 6 ; cyclophosphamide 250 mg/m^2 IV Days 2 , 3 4 Cycle 1 Days 1 , 2 3 Cycles 2 - 6 ) 28 day cycle .</brief_summary>
	<brief_title>A Study Obinutuzumab ( GA101 ; RO5072759 ) Combination With Chemotherapy Participants With Previously Untreated Chronic Lymphocytic Leukemia ( CLL ) ( GALTON )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Confirmed diagnosis CD20positive BCLL Rai Stage III/IV Binet Stage C disease Rai Stage I/II Binet Stage B disease require treatment Adequate baseline bone marrow function , unless clear evidence extensive bone marrow involvement tumor infiltration , myelodysplasia , hypocellularity No previous treatment CLL chemotherapy , radiotherapy , immunotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy great ( &gt; ) 6 month Treatment investigational agent participation another clinical trial within 28 day prior start Cycle 1 Transformation CLL aggressive Bcell malignancy Creatinine clearance less equal ( &lt; = ) 60 milliliter per minute ( mL/min ) , calculate accord formula Cockcroft Gault Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) Total bilirubin great equal ( &gt; = ) 3 x ULN History severe allergic anaphylactic reaction monoclonal antibody therapy History sensitivity mannitol ( bendamustine administer ) History malignancy could affect compliance protocol interpretation result Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease pulmonary disease Known active bacterial , viral , fungal , mycobacterial , infection ( exclude fungal infection nail bed ) major episode infection require treatment IV antibiotic hospitalization ( related completion course antibiotic ) within 4 week start Cycle 1 Recent major surgery ( within 4 week prior start Cycle 1 ) , diagnosis Known infection human immunodeficiency virus ( HIV ) seropositive status Presence positive test result hepatitis B ( hepatitis B virus [ HBV ] surface antigen [ HBsAg ] and/or total hepatitis B core antibody [ antiHBc ] ) hepatitis C ( hepatitis C virus [ HCV ] antibody serology test ) . Participants chronic HBV infection , occult HBV infection , past HBV infection exclude . Participants receive IV immunoglobulin within 3 month enrollment antiHBc positive HBV deoxyribonucleic acid ( DNA ) negative consider inclusion study Medical Monitor casebycase basis . Participants positive HCV antibody eligible polymerase chain reaction ( PCR ) negative HCV ribonucleic acid ( RNA ) . Women pregnant lactate Fertile men woman childbearing potential unless 1 ) surgically sterile 2 ) use adequate measure contraception oral contraceptive , intrauterine device , barrier method contraception conjunction spermicidal jelly Concurrent ( within 7 day prior first dose study treatment ) systemic corticosteroid use except lowdose corticosteroid therapy use treat illness lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>